9298436 Canada Inc.
$2,906,106.67
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
EF 2020-2021
Canada
Development of a Nasal Vaccine for the prevention of coronavirus disease 2019 due to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).